Based on above researches, it is suggested that IFN-β 1a/b, Dimethyl fumarate and Natalizumab may be effective in the treatment of virus-induced MS by regulating Type I IFN pathway, IL-17, CD4+ and CD8+ T cells, Teriflunomide may not play much of a role, and Glatiramer acetate may even be shown to play the opposite role. This evidence concerns the gene IL17A and myeloid sarcoma.